DRAFT RFP TRICARE Pharmacy Services, 5th Generation (TPharm5)

Closed Special Notice Posted

This opportunity was awarded. See the award notice from , or the latest solicitation from .

Solicitation number
HT940220R0002
Agency
Defense Health Agency Department of Defense
Responses due
Set-aside
No set-aside

Opportunity facts

NAICS code
446110 Pharmacies and Drug Stores
Place of performance
USA

Notice details come from SAM.gov. Updated .

About this opportunity

Written by GovTribe AI ·

The Special Notice was published by the Defense Health Agency and concerns a draft request for proposals for the TRICARE Pharmacy Services, Fifth Generation contract (TPharm5). The Defense Health Agency manages the Military Health System and oversees the TRICARE pharmacy program.

The Special Notice provides the draft RFP sections and attachments to notify potential offerors and obtain industry feedback on requirements and approach. Key details include that comments from interested vendors are requested on the draft RFP, with a deadline of January 17, 2020. Specifically, feedback is sought on the use of statements of objectives, management of specialty pharmacy services, standards for retail pharmacy network access, policies regarding compounded medications, care coordination programs, patient safety notifications, and quality control requirements. An optional information session to discuss the draft RFP was also announced for December 11, 2019. The agency estimates releasing a formal solicitation in mid-2020 to award a new stand-alone pharmacy services contract to provide fixed unit priced services for the TRICARE pharmacy program for an estimated total period of performance of nine years.

Notice text

7 versions

As posted on SAM.gov.

Update #7 · Latest ·

06/10/2020

REMINDER: As communicated during the December 2019 Info Session and in draft RFP documents, offerors must complete additional paperwork and approvals in order to obtain protected data to support proposal preparation and submission. Offerors are strongly advised to execute this process as soon as possible before RFP release, as approval timelines can take several weeks or more.

  1. Please consult Attachment L-1 from the draft RFP for preliminary instructions on submitting Non-Disclosure Agreements (NDAs; Attachment L-1.2) and a Business Associate Agreement (BAA; Attachment L-1.3) to the TPharm5 email inbox as soon as possible.
  2. In addition to the NDAs and BAA, the offeror will complete a Data Sharing Agreement Application (DSAA) and System Security Verification (SSV) detailing intended use and protection of the data, and technical specifications of non-DoD systems that may be used to receive, store, transmit, or otherwise handle the data.
  3. The offeror will submit the DSAA and SSV package to the TPharm5 email inbox for preliminary review and initial Government Sponsor approval.
  4. Upon initial Government Sponsor approval, the offeror will submit its completed DSAA and SSV package to the DHA Privacy and Civil Liberties Office for a thorough privacy and technical review, final approval, and issuance of a formal Data Sharing Agreement (DSA).

The DSAA and SSV templates have been posted to beta.SAM.gov. Frequently Asked Questions, contact information for the DHA Privacy and Civil Liberties Office, and additional resources are available at the following link: https://www.health.mil/Military-Health-Topics/Privacy-and-Civil-Liberties/Submit-a-Data-Sharing-Application

Please note: the TPharm5 team can address basic questions about anticipated data types and transmission methods but is not authorized to advise on questions of a technical or legal nature and cannot validate sufficiency of DSAA/SSV applications; offerors are encouraged to engage directly with the DHA Privacy and Civil Liberties Office for assistance on such matters. In addition, please be aware that the government may use alternate secure data transfer methods than those described in Attachment L-1, such as the Procurement Integrity Enterprise Environment (PIEE) Solicitation Module, for which additional instructions will be provided if applicable.

05/15/2020

Uploaded additional Q&A regarding CAS coverage and associated clauses.

05/04/2020

Uploaded Government responses to comments/questions on revised draft Section C.

04/06/2020

Uploaded Revised Draft Section C and Overview of Changes for comment. DHA requests responders submit any questions or comments about the DRAFT Section C revisions via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil by April 20, 2020.

************************************
03/18/2020

Uploaded Government responses to Industry questions on draft RFP

************************************
12/16/2019

Uploaded slides from 12/11/2019 Info Session

************************************

TRICARE Pharmacy Services, 5th Generation (TPharm5)
DRAFT Request for Proposals (RFP)
HT940220R0002

The Defense Health Agency (DHA) is a joint, integrated DoD Combat Support Agency that enables the US Army, US Navy, and US Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime.  The DHA supports the delivery of integrated, affordable, and high quality health services to Military Health System (MHS) beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS by:  Implementing shared services with common measurement of outcomes; enabling rapid adoption of proven practices, helping reduce unwanted variation, and improving the coordination of care across time and treatment venues.

The Defense Health Agency (DHA) is contemplating a new follow-on stand-alone Pharmacy services contract with fixed unit prices for the TRICARE Pharmacy Program, 5th Generation.  DHA anticipates the contract will include an 18-month base period for transition-in, seven 1-year option periods for health care delivery, with 1-year concurrent contract phase out activities, and a potential 6-month extension of services permitted per FAR Clause 52.217-8, Option to Extend Services, for a potential total allowable period of performance of 9 years.  The purpose of this notice is to provide potential offerors with the DRAFT TPharm5 Request for Proposal (RFP); attached to this notice are Sections B – M and Section L and J attachments.  This posting is intended solely for information and planning purposes only, and is NOT a solicitation.  Schedule B is provided only to share the Government’s concept regarding CLIN structure as known at this time (estimated quantities are entirely notional). DHA is seeking industry feedback and recommendations on its description of the TPharm5 requirements, and its approach in the draft RFP documents attached.  Potential offerors are invited to review the DRAFT RFP documents and provide questions and comments.  DHA requests that responders identify the specific solicitation document, and cite specific paragraphs where appropriate when providing additional questions or comments.

DHA will consider industry's comments to revise its approach for TPharm5 to provide high quality pharmacy services to TRICARE beneficiaries within the statutory and regulatory limitations governing this entitlement program.  DHA requests responders submit any questions or comments about the DRAFT RFP via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil no later than COB 17 January 2020; include “DRAFT TPharm5 HT9402-20-R-0002” in the subject line.  

In particular, DHA would like to draw interested vendors’ attention to the following Sections in the DRAFT RFP for review and comment:

  1. §C.1.1.1 Use of Statements of Objectives
  2. §C.3.3 Specialty
  3. §C.3.4.2 Retail Network Access
  4. §C.6.3.5 Compounded Medications
  5. §C.6.3.6 Care Coordination
  6. §C.7.11.2 Patient Safety Notification
  7. §C.13.1.1 Quality Control

DHA is not issuing a solicitation at this time, and this notice shall not be construed as DHA's commitment to issue a solicitation nor does it restrict DHA to a particular acquisition approach. Interested parties shall not send proposals in response to this notice, nor shall they contact any other individuals about this Notice or the TPharm5 requirement.  Any information provided to DHA is strictly voluntary and given with no expectation of compensation, and is clearly provided at no cost to the Government.  If DHA issues a solicitation, DHA will conduct any source selection in accordance with the Federal Acquisition Regulation (FAR) 15, as supplemented, at Managed Care - Contract Division (MC-CD), in Aurora, Colorado.  DHA estimates it may issue a formal solicitation mid-2020 on the Beta.SAM.gov Contract Opportunities (https://beta.sam.gov) website.  Any future information on this acquisition will be posted on Beta.SAM.gov Contract Opportunities.  It is the responsibility of the prospective offeror to review this site regularly for updates and/or changes.

TPharm5 DRAFT RFP Info Session

DHA will host an info session for the TPharm5 draft RFP on December 11, 2019 from 1400-1600 EST.

Participants may submit questions in advance of the info session to the TPharm5 mailbox dha.buckley.acquis-procure.mbx.tpharm5@mail.mil.  Slides and any information provided during the info session will be posted to this notice on BETA.SAM.gov.

Participants may join the web session via: https://ldd.adobeconnect.com/tpharm5/

Participants may join the audio session via: 1-888-928-9122, Participant Code: 9249445#

Participation in groups is encouraged to reduce the number of individual sessions created.

Update #6 ·

05/15/2020

Uploaded additional Q&A regarding CAS coverage and associated clauses.

05/04/2020

Uploaded Government responses to comments/questions on revised draft Section C.

04/06/2020

Uploaded Revised Draft Section C and Overview of Changes for comment. DHA requests responders submit any questions or comments about the DRAFT Section C revisions via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil by April 20, 2020.

************************************
03/18/2020

Uploaded Government responses to Industry questions on draft RFP

************************************
12/16/2019

Uploaded slides from 12/11/2019 Info Session

************************************

TRICARE Pharmacy Services, 5th Generation (TPharm5)
DRAFT Request for Proposals (RFP)
HT940220R0002

The Defense Health Agency (DHA) is a joint, integrated DoD Combat Support Agency that enables the US Army, US Navy, and US Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime.  The DHA supports the delivery of integrated, affordable, and high quality health services to Military Health System (MHS) beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS by:  Implementing shared services with common measurement of outcomes; enabling rapid adoption of proven practices, helping reduce unwanted variation, and improving the coordination of care across time and treatment venues.

The Defense Health Agency (DHA) is contemplating a new follow-on stand-alone Pharmacy services contract with fixed unit prices for the TRICARE Pharmacy Program, 5th Generation.  DHA anticipates the contract will include an 18-month base period for transition-in, seven 1-year option periods for health care delivery, with 1-year concurrent contract phase out activities, and a potential 6-month extension of services permitted per FAR Clause 52.217-8, Option to Extend Services, for a potential total allowable period of performance of 9 years.  The purpose of this notice is to provide potential offerors with the DRAFT TPharm5 Request for Proposal (RFP); attached to this notice are Sections B – M and Section L and J attachments.  This posting is intended solely for information and planning purposes only, and is NOT a solicitation.  Schedule B is provided only to share the Government’s concept regarding CLIN structure as known at this time (estimated quantities are entirely notional). DHA is seeking industry feedback and recommendations on its description of the TPharm5 requirements, and its approach in the draft RFP documents attached.  Potential offerors are invited to review the DRAFT RFP documents and provide questions and comments.  DHA requests that responders identify the specific solicitation document, and cite specific paragraphs where appropriate when providing additional questions or comments.

DHA will consider industry's comments to revise its approach for TPharm5 to provide high quality pharmacy services to TRICARE beneficiaries within the statutory and regulatory limitations governing this entitlement program.  DHA requests responders submit any questions or comments about the DRAFT RFP via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil no later than COB 17 January 2020; include “DRAFT TPharm5 HT9402-20-R-0002” in the subject line.  

In particular, DHA would like to draw interested vendors’ attention to the following Sections in the DRAFT RFP for review and comment:

  1. §C.1.1.1 Use of Statements of Objectives
  2. §C.3.3 Specialty
  3. §C.3.4.2 Retail Network Access
  4. §C.6.3.5 Compounded Medications
  5. §C.6.3.6 Care Coordination
  6. §C.7.11.2 Patient Safety Notification
  7. §C.13.1.1 Quality Control

DHA is not issuing a solicitation at this time, and this notice shall not be construed as DHA's commitment to issue a solicitation nor does it restrict DHA to a particular acquisition approach. Interested parties shall not send proposals in response to this notice, nor shall they contact any other individuals about this Notice or the TPharm5 requirement.  Any information provided to DHA is strictly voluntary and given with no expectation of compensation, and is clearly provided at no cost to the Government.  If DHA issues a solicitation, DHA will conduct any source selection in accordance with the Federal Acquisition Regulation (FAR) 15, as supplemented, at Managed Care - Contract Division (MC-CD), in Aurora, Colorado.  DHA estimates it may issue a formal solicitation mid-2020 on the Beta.SAM.gov Contract Opportunities (https://beta.sam.gov) website.  Any future information on this acquisition will be posted on Beta.SAM.gov Contract Opportunities.  It is the responsibility of the prospective offeror to review this site regularly for updates and/or changes.

TPharm5 DRAFT RFP Info Session

DHA will host an info session for the TPharm5 draft RFP on December 11, 2019 from 1400-1600 EST.

Participants may submit questions in advance of the info session to the TPharm5 mailbox dha.buckley.acquis-procure.mbx.tpharm5@mail.mil.  Slides and any information provided during the info session will be posted to this notice on BETA.SAM.gov.

Participants may join the web session via: https://ldd.adobeconnect.com/tpharm5/

Participants may join the audio session via: 1-888-928-9122, Participant Code: 9249445#

Participation in groups is encouraged to reduce the number of individual sessions created.

Update #5 ·

05/04/2020

Uploaded Government responses to comments/questions on revised draft Section C.

04/06/2020

Uploaded Revised Draft Section C and Overview of Changes for comment. DHA requests responders submit any questions or comments about the DRAFT Section C revisions via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil by April 20, 2020.

************************************
03/18/2020

Uploaded Government responses to Industry questions on draft RFP

************************************
12/16/2019

Uploaded slides from 12/11/2019 Info Session

************************************

TRICARE Pharmacy Services, 5th Generation (TPharm5)
DRAFT Request for Proposals (RFP)
HT940220R0002

The Defense Health Agency (DHA) is a joint, integrated DoD Combat Support Agency that enables the US Army, US Navy, and US Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime.  The DHA supports the delivery of integrated, affordable, and high quality health services to Military Health System (MHS) beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS by:  Implementing shared services with common measurement of outcomes; enabling rapid adoption of proven practices, helping reduce unwanted variation, and improving the coordination of care across time and treatment venues.

The Defense Health Agency (DHA) is contemplating a new follow-on stand-alone Pharmacy services contract with fixed unit prices for the TRICARE Pharmacy Program, 5th Generation.  DHA anticipates the contract will include an 18-month base period for transition-in, seven 1-year option periods for health care delivery, with 1-year concurrent contract phase out activities, and a potential 6-month extension of services permitted per FAR Clause 52.217-8, Option to Extend Services, for a potential total allowable period of performance of 9 years.  The purpose of this notice is to provide potential offerors with the DRAFT TPharm5 Request for Proposal (RFP); attached to this notice are Sections B – M and Section L and J attachments.  This posting is intended solely for information and planning purposes only, and is NOT a solicitation.  Schedule B is provided only to share the Government’s concept regarding CLIN structure as known at this time (estimated quantities are entirely notional). DHA is seeking industry feedback and recommendations on its description of the TPharm5 requirements, and its approach in the draft RFP documents attached.  Potential offerors are invited to review the DRAFT RFP documents and provide questions and comments.  DHA requests that responders identify the specific solicitation document, and cite specific paragraphs where appropriate when providing additional questions or comments.

DHA will consider industry's comments to revise its approach for TPharm5 to provide high quality pharmacy services to TRICARE beneficiaries within the statutory and regulatory limitations governing this entitlement program.  DHA requests responders submit any questions or comments about the DRAFT RFP via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil no later than COB 17 January 2020; include “DRAFT TPharm5 HT9402-20-R-0002” in the subject line.  

In particular, DHA would like to draw interested vendors’ attention to the following Sections in the DRAFT RFP for review and comment:

  1. §C.1.1.1 Use of Statements of Objectives
  2. §C.3.3 Specialty
  3. §C.3.4.2 Retail Network Access
  4. §C.6.3.5 Compounded Medications
  5. §C.6.3.6 Care Coordination
  6. §C.7.11.2 Patient Safety Notification
  7. §C.13.1.1 Quality Control

DHA is not issuing a solicitation at this time, and this notice shall not be construed as DHA's commitment to issue a solicitation nor does it restrict DHA to a particular acquisition approach. Interested parties shall not send proposals in response to this notice, nor shall they contact any other individuals about this Notice or the TPharm5 requirement.  Any information provided to DHA is strictly voluntary and given with no expectation of compensation, and is clearly provided at no cost to the Government.  If DHA issues a solicitation, DHA will conduct any source selection in accordance with the Federal Acquisition Regulation (FAR) 15, as supplemented, at Managed Care - Contract Division (MC-CD), in Aurora, Colorado.  DHA estimates it may issue a formal solicitation mid-2020 on the Beta.SAM.gov Contract Opportunities (https://beta.sam.gov) website.  Any future information on this acquisition will be posted on Beta.SAM.gov Contract Opportunities.  It is the responsibility of the prospective offeror to review this site regularly for updates and/or changes.

TPharm5 DRAFT RFP Info Session

DHA will host an info session for the TPharm5 draft RFP on December 11, 2019 from 1400-1600 EST.

Participants may submit questions in advance of the info session to the TPharm5 mailbox dha.buckley.acquis-procure.mbx.tpharm5@mail.mil.  Slides and any information provided during the info session will be posted to this notice on BETA.SAM.gov.

Participants may join the web session via: https://ldd.adobeconnect.com/tpharm5/

Participants may join the audio session via: 1-888-928-9122, Participant Code: 9249445#

Participation in groups is encouraged to reduce the number of individual sessions created.

Update #4 ·

04/06/2020

Uploaded Revised Draft Section C and Overview of Changes for comment. DHA requests responders submit any questions or comments about the DRAFT Section C revisions via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil by April 20, 2020.

************************************
03/18/2020

Uploaded Government responses to Industry questions on draft RFP

************************************
12/16/2019

Uploaded slides from 12/11/2019 Info Session

************************************

TRICARE Pharmacy Services, 5th Generation (TPharm5)
DRAFT Request for Proposals (RFP)
HT940220R0002

The Defense Health Agency (DHA) is a joint, integrated DoD Combat Support Agency that enables the US Army, US Navy, and US Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime.  The DHA supports the delivery of integrated, affordable, and high quality health services to Military Health System (MHS) beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS by:  Implementing shared services with common measurement of outcomes; enabling rapid adoption of proven practices, helping reduce unwanted variation, and improving the coordination of care across time and treatment venues.

The Defense Health Agency (DHA) is contemplating a new follow-on stand-alone Pharmacy services contract with fixed unit prices for the TRICARE Pharmacy Program, 5th Generation.  DHA anticipates the contract will include an 18-month base period for transition-in, seven 1-year option periods for health care delivery, with 1-year concurrent contract phase out activities, and a potential 6-month extension of services permitted per FAR Clause 52.217-8, Option to Extend Services, for a potential total allowable period of performance of 9 years.  The purpose of this notice is to provide potential offerors with the DRAFT TPharm5 Request for Proposal (RFP); attached to this notice are Sections B – M and Section L and J attachments.  This posting is intended solely for information and planning purposes only, and is NOT a solicitation.  Schedule B is provided only to share the Government’s concept regarding CLIN structure as known at this time (estimated quantities are entirely notional). DHA is seeking industry feedback and recommendations on its description of the TPharm5 requirements, and its approach in the draft RFP documents attached.  Potential offerors are invited to review the DRAFT RFP documents and provide questions and comments.  DHA requests that responders identify the specific solicitation document, and cite specific paragraphs where appropriate when providing additional questions or comments.

DHA will consider industry's comments to revise its approach for TPharm5 to provide high quality pharmacy services to TRICARE beneficiaries within the statutory and regulatory limitations governing this entitlement program.  DHA requests responders submit any questions or comments about the DRAFT RFP via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil no later than COB 17 January 2020; include “DRAFT TPharm5 HT9402-20-R-0002” in the subject line.  

In particular, DHA would like to draw interested vendors’ attention to the following Sections in the DRAFT RFP for review and comment:

  1. §C.1.1.1 Use of Statements of Objectives
  2. §C.3.3 Specialty
  3. §C.3.4.2 Retail Network Access
  4. §C.6.3.5 Compounded Medications
  5. §C.6.3.6 Care Coordination
  6. §C.7.11.2 Patient Safety Notification
  7. §C.13.1.1 Quality Control

DHA is not issuing a solicitation at this time, and this notice shall not be construed as DHA's commitment to issue a solicitation nor does it restrict DHA to a particular acquisition approach. Interested parties shall not send proposals in response to this notice, nor shall they contact any other individuals about this Notice or the TPharm5 requirement.  Any information provided to DHA is strictly voluntary and given with no expectation of compensation, and is clearly provided at no cost to the Government.  If DHA issues a solicitation, DHA will conduct any source selection in accordance with the Federal Acquisition Regulation (FAR) 15, as supplemented, at Managed Care - Contract Division (MC-CD), in Aurora, Colorado.  DHA estimates it may issue a formal solicitation mid-2020 on the Beta.SAM.gov Contract Opportunities (https://beta.sam.gov) website.  Any future information on this acquisition will be posted on Beta.SAM.gov Contract Opportunities.  It is the responsibility of the prospective offeror to review this site regularly for updates and/or changes.

TPharm5 DRAFT RFP Info Session

DHA will host an info session for the TPharm5 draft RFP on December 11, 2019 from 1400-1600 EST.

Participants may submit questions in advance of the info session to the TPharm5 mailbox dha.buckley.acquis-procure.mbx.tpharm5@mail.mil.  Slides and any information provided during the info session will be posted to this notice on BETA.SAM.gov.

Participants may join the web session via: https://ldd.adobeconnect.com/tpharm5/

Participants may join the audio session via: 1-888-928-9122, Participant Code: 9249445#

Participation in groups is encouraged to reduce the number of individual sessions created.

Update #3 ·

03/18/2020

Uploaded Government responses to Industry questions on draft RFP

************************************
12/16/2019

Uploaded slides from 12/11/2019 Info Session

************************************

TRICARE Pharmacy Services, 5th Generation (TPharm5)
DRAFT Request for Proposals (RFP)
HT940220R0002

The Defense Health Agency (DHA) is a joint, integrated DoD Combat Support Agency that enables the US Army, US Navy, and US Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime.  The DHA supports the delivery of integrated, affordable, and high quality health services to Military Health System (MHS) beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS by:  Implementing shared services with common measurement of outcomes; enabling rapid adoption of proven practices, helping reduce unwanted variation, and improving the coordination of care across time and treatment venues.

The Defense Health Agency (DHA) is contemplating a new follow-on stand-alone Pharmacy services contract with fixed unit prices for the TRICARE Pharmacy Program, 5th Generation.  DHA anticipates the contract will include an 18-month base period for transition-in, seven 1-year option periods for health care delivery, with 1-year concurrent contract phase out activities, and a potential 6-month extension of services permitted per FAR Clause 52.217-8, Option to Extend Services, for a potential total allowable period of performance of 9 years.  The purpose of this notice is to provide potential offerors with the DRAFT TPharm5 Request for Proposal (RFP); attached to this notice are Sections B – M and Section L and J attachments.  This posting is intended solely for information and planning purposes only, and is NOT a solicitation.  Schedule B is provided only to share the Government’s concept regarding CLIN structure as known at this time (estimated quantities are entirely notional). DHA is seeking industry feedback and recommendations on its description of the TPharm5 requirements, and its approach in the draft RFP documents attached.  Potential offerors are invited to review the DRAFT RFP documents and provide questions and comments.  DHA requests that responders identify the specific solicitation document, and cite specific paragraphs where appropriate when providing additional questions or comments.

DHA will consider industry's comments to revise its approach for TPharm5 to provide high quality pharmacy services to TRICARE beneficiaries within the statutory and regulatory limitations governing this entitlement program.  DHA requests responders submit any questions or comments about the DRAFT RFP via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil no later than COB 17 January 2020; include “DRAFT TPharm5 HT9402-20-R-0002” in the subject line.  

In particular, DHA would like to draw interested vendors’ attention to the following Sections in the DRAFT RFP for review and comment:

  1. §C.1.1.1 Use of Statements of Objectives
  2. §C.3.3 Specialty
  3. §C.3.4.2 Retail Network Access
  4. §C.6.3.5 Compounded Medications
  5. §C.6.3.6 Care Coordination
  6. §C.7.11.2 Patient Safety Notification
  7. §C.13.1.1 Quality Control

DHA is not issuing a solicitation at this time, and this notice shall not be construed as DHA's commitment to issue a solicitation nor does it restrict DHA to a particular acquisition approach. Interested parties shall not send proposals in response to this notice, nor shall they contact any other individuals about this Notice or the TPharm5 requirement.  Any information provided to DHA is strictly voluntary and given with no expectation of compensation, and is clearly provided at no cost to the Government.  If DHA issues a solicitation, DHA will conduct any source selection in accordance with the Federal Acquisition Regulation (FAR) 15, as supplemented, at Managed Care - Contract Division (MC-CD), in Aurora, Colorado.  DHA estimates it may issue a formal solicitation mid-2020 on the Beta.SAM.gov Contract Opportunities (https://beta.sam.gov) website.  Any future information on this acquisition will be posted on Beta.SAM.gov Contract Opportunities.  It is the responsibility of the prospective offeror to review this site regularly for updates and/or changes.

TPharm5 DRAFT RFP Info Session

DHA will host an info session for the TPharm5 draft RFP on December 11, 2019 from 1400-1600 EST.

Participants may submit questions in advance of the info session to the TPharm5 mailbox dha.buckley.acquis-procure.mbx.tpharm5@mail.mil.  Slides and any information provided during the info session will be posted to this notice on BETA.SAM.gov.

Participants may join the web session via: https://ldd.adobeconnect.com/tpharm5/

Participants may join the audio session via: 1-888-928-9122, Participant Code: 9249445#

Participation in groups is encouraged to reduce the number of individual sessions created.

Update #2 ·

************************************
12/16/2019

Uploaded slides from 12/11/2019 Info Session

************************************

TRICARE Pharmacy Services, 5th Generation (TPharm5)
DRAFT Request for Proposals (RFP)
HT940220R0002

The Defense Health Agency (DHA) is a joint, integrated DoD Combat Support Agency that enables the US Army, US Navy, and US Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime.  The DHA supports the delivery of integrated, affordable, and high quality health services to Military Health System (MHS) beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS by:  Implementing shared services with common measurement of outcomes; enabling rapid adoption of proven practices, helping reduce unwanted variation, and improving the coordination of care across time and treatment venues.

The Defense Health Agency (DHA) is contemplating a new follow-on stand-alone Pharmacy services contract with fixed unit prices for the TRICARE Pharmacy Program, 5th Generation.  DHA anticipates the contract will include an 18-month base period for transition-in, seven 1-year option periods for health care delivery, with 1-year concurrent contract phase out activities, and a potential 6-month extension of services permitted per FAR Clause 52.217-8, Option to Extend Services, for a potential total allowable period of performance of 9 years.  The purpose of this notice is to provide potential offerors with the DRAFT TPharm5 Request for Proposal (RFP); attached to this notice are Sections B – M and Section L and J attachments.  This posting is intended solely for information and planning purposes only, and is NOT a solicitation.  Schedule B is provided only to share the Government’s concept regarding CLIN structure as known at this time (estimated quantities are entirely notional). DHA is seeking industry feedback and recommendations on its description of the TPharm5 requirements, and its approach in the draft RFP documents attached.  Potential offerors are invited to review the DRAFT RFP documents and provide questions and comments.  DHA requests that responders identify the specific solicitation document, and cite specific paragraphs where appropriate when providing additional questions or comments.

DHA will consider industry's comments to revise its approach for TPharm5 to provide high quality pharmacy services to TRICARE beneficiaries within the statutory and regulatory limitations governing this entitlement program.  DHA requests responders submit any questions or comments about the DRAFT RFP via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil no later than COB 17 January 2020; include “DRAFT TPharm5 HT9402-20-R-0002” in the subject line.  

In particular, DHA would like to draw interested vendors’ attention to the following Sections in the DRAFT RFP for review and comment:

  1. §C.1.1.1 Use of Statements of Objectives
  2. §C.3.3 Specialty
  3. §C.3.4.2 Retail Network Access
  4. §C.6.3.5 Compounded Medications
  5. §C.6.3.6 Care Coordination
  6. §C.7.11.2 Patient Safety Notification
  7. §C.13.1.1 Quality Control

DHA is not issuing a solicitation at this time, and this notice shall not be construed as DHA's commitment to issue a solicitation nor does it restrict DHA to a particular acquisition approach. Interested parties shall not send proposals in response to this notice, nor shall they contact any other individuals about this Notice or the TPharm5 requirement.  Any information provided to DHA is strictly voluntary and given with no expectation of compensation, and is clearly provided at no cost to the Government.  If DHA issues a solicitation, DHA will conduct any source selection in accordance with the Federal Acquisition Regulation (FAR) 15, as supplemented, at Managed Care - Contract Division (MC-CD), in Aurora, Colorado.  DHA estimates it may issue a formal solicitation mid-2020 on the Beta.SAM.gov Contract Opportunities (https://beta.sam.gov) website.  Any future information on this acquisition will be posted on Beta.SAM.gov Contract Opportunities.  It is the responsibility of the prospective offeror to review this site regularly for updates and/or changes.

TPharm5 DRAFT RFP Info Session

DHA will host an info session for the TPharm5 draft RFP on December 11, 2019 from 1400-1600 EST.

Participants may submit questions in advance of the info session to the TPharm5 mailbox dha.buckley.acquis-procure.mbx.tpharm5@mail.mil.  Slides and any information provided during the info session will be posted to this notice on BETA.SAM.gov.

Participants may join the web session via: https://ldd.adobeconnect.com/tpharm5/

Participants may join the audio session via: 1-888-928-9122, Participant Code: 9249445#

Participation in groups is encouraged to reduce the number of individual sessions created.

Update #1 ·

TRICARE Pharmacy Services, 5th Generation (TPharm5)
DRAFT Request for Proposals (RFP)
HT940220R0002

The Defense Health Agency (DHA) is a joint, integrated DoD Combat Support Agency that enables the US Army, US Navy, and US Air Force medical services to provide a medically ready force and ready medical force to Combatant Commands in both peacetime and wartime.  The DHA supports the delivery of integrated, affordable, and high quality health services to Military Health System (MHS) beneficiaries and is responsible for driving greater integration of clinical and business processes across the MHS by:  Implementing shared services with common measurement of outcomes; enabling rapid adoption of proven practices, helping reduce unwanted variation, and improving the coordination of care across time and treatment venues.

The Defense Health Agency (DHA) is contemplating a new follow-on stand-alone Pharmacy services contract with fixed unit prices for the TRICARE Pharmacy Program, 5th Generation.  DHA anticipates the contract will include an 18-month base period for transition-in, seven 1-year option periods for health care delivery, with 1-year concurrent contract phase out activities, and a potential 6-month extension of services permitted per FAR Clause 52.217-8, Option to Extend Services, for a potential total allowable period of performance of 9 years.  The purpose of this notice is to provide potential offerors with the DRAFT TPharm5 Request for Proposal (RFP); attached to this notice are Sections B – M and Section L and J attachments.  This posting is intended solely for information and planning purposes only, and is NOT a solicitation.  Schedule B is provided only to share the Government’s concept regarding CLIN structure as known at this time (estimated quantities are entirely notional). DHA is seeking industry feedback and recommendations on its description of the TPharm5 requirements, and its approach in the draft RFP documents attached.  Potential offerors are invited to review the DRAFT RFP documents and provide questions and comments.  DHA requests that responders identify the specific solicitation document, and cite specific paragraphs where appropriate when providing additional questions or comments.

DHA will consider industry's comments to revise its approach for TPharm5 to provide high quality pharmacy services to TRICARE beneficiaries within the statutory and regulatory limitations governing this entitlement program.  DHA requests responders submit any questions or comments about the DRAFT RFP via email to Ms. Hilary Meckel, Contracting Officer, dha.buckley.acquis-procure.mbx.tpharm5@mail.mil no later than COB 17 January 2020; include “DRAFT TPharm5 HT9402-20-R-0002” in the subject line.  

In particular, DHA would like to draw interested vendors’ attention to the following Sections in the DRAFT RFP for review and comment:

  1. §C.1.1.1 Use of Statements of Objectives
  2. §C.3.3 Specialty
  3. §C.3.4.2 Retail Network Access
  4. §C.6.3.5 Compounded Medications
  5. §C.6.3.6 Care Coordination
  6. §C.7.11.2 Patient Safety Notification
  7. §C.13.1.1 Quality Control

DHA is not issuing a solicitation at this time, and this notice shall not be construed as DHA's commitment to issue a solicitation nor does it restrict DHA to a particular acquisition approach. Interested parties shall not send proposals in response to this notice, nor shall they contact any other individuals about this Notice or the TPharm5 requirement.  Any information provided to DHA is strictly voluntary and given with no expectation of compensation, and is clearly provided at no cost to the Government.  If DHA issues a solicitation, DHA will conduct any source selection in accordance with the Federal Acquisition Regulation (FAR) 15, as supplemented, at Managed Care - Contract Division (MC-CD), in Aurora, Colorado.  DHA estimates it may issue a formal solicitation mid-2020 on the Beta.SAM.gov Contract Opportunities (https://beta.sam.gov) website.  Any future information on this acquisition will be posted on Beta.SAM.gov Contract Opportunities.  It is the responsibility of the prospective offeror to review this site regularly for updates and/or changes.

TPharm5 DRAFT RFP Info Session

DHA will host an info session for the TPharm5 draft RFP on December 11, 2019 from 1400-1600 EST.

Participants may submit questions in advance of the info session to the TPharm5 mailbox dha.buckley.acquis-procure.mbx.tpharm5@mail.mil.  Slides and any information provided during the info session will be posted to this notice on BETA.SAM.gov.

Participants may join the web session via: https://ldd.adobeconnect.com/tpharm5/

Participants may join the audio session via: 1-888-928-9122, Participant Code: 9249445#

Participation in groups is encouraged to reduce the number of individual sessions created.

Attachments

File Type Posted
QA CAS Applicability Specific Clauses (May 15 2020).pdf PDF
Responses to Industry on Revised Draft Section C 20200504.pdf PDF
TPharm5 - Overview of Changes to Draft Section C.DOCX DOCX document
DHA Responses to Industry on Draft RFP 20200318.pdf PDF
Data Pkg 13 - MTF Claims Volumes by Site.xlsx XLSX spreadsheet
Attachment L-3 Specialty Reimbursement for Use in Determining Incentiv....docx DOCX document
Attachment L-9 Benefit Design Document_TPharm5.xlsx XLSX spreadsheet
Attachment L-2 Retail Network Reimbursement Table.docx DOCX document
TPharm5 Draft RFP READ FIRST 20191202.docx DOCX document
Tpharm5 Draft Section G 20191202.docx DOCX document
Attachment L-8 MMC Sample File.xlsx XLSX spreadsheet
Attachment L-9.8 PA_ST_QL List.XLSX XLSX spreadsheet
Attachment L-4 Negotiated Specialty Retail Replenished Dispensing Fees.docx DOCX document
Attachment L-9.9 Fluoride Products List.xlsx XLSX spreadsheet
Attachment L-12 IHS_Pharmacy_Listing_2019.xlsx XLSX spreadsheet
Data Pkg 15 IHS_Pharmacy_Claims_Volume_2017_&_2018.xlsx XLSX spreadsheet
TPharm5 Draft Section E 20191120.docx DOCX document
TPharm5 Draft Section D 20191120.docx DOCX document
Attachment L-1.1 List of Data Packages.docx DOCX document
Attachment L-19 Past Performance Questionnaire Template Tab F 20191120.docx DOCX document
Data Pkg 7 Specialty Drug Utilization, Retail and Mail.xlsx XLSX spreadsheet
Data Pkg 14 Retail Claims with COB.xlsx XLSX spreadsheet
Attachment J-5 TPharm5 Award Fee Plan 20191122.docx DOCX document
Data Pkg 5 MOP Utilization by Drug.xlsx XLSX spreadsheet
Data Pkg 23 - Paid Claims and Rejects - MHS GENESIS.xlsx XLSX spreadsheet
Data Pkg 22 - Paid Claims and Rejects - Retail.xlsx XLSX spreadsheet
Data Pkg 24 - CHCBP Volume.xlsx XLSX spreadsheet
Attachment L-9.6 Self-Admin Injectables List.xlsx XLSX spreadsheet
Attachment L-9.7 Expanded Use of MTF and TMOP List.xlsx XLSX spreadsheet
Attachment L-18 CDRL Supplemental Bid Schedule.xlsx XLSX spreadsheet
Attachment L-1 Ordering Instructions for Data Files not on SAM.gov.docx DOCX document
TPharm5 Draft Section L 20191202.docx DOCX document
Data Pkg 25 - OHI Development.xlsx XLSX spreadsheet
Attachment L-9.5 Non-Formulary List.xlsx XLSX spreadsheet
Data Pkg 9 Customer_Service_Volume.xlsx XLSX spreadsheet
Data Pkg 16 VA_VA CHDR Volume.xlsx XLSX spreadsheet
Attachment J-2 Acronym List.docx DOCX document
Attachment J-3 Website Links.docx DOCX document
Attachment L-5 Guaranty_Agreement.pdf PDF
Attachment L-7 Teaming Subcontractor Consent Ltr.docx DOCX document
Attachment L-9.3 Covered OTCs - Purchased Care.xlsx XLSX spreadsheet
Attachment L-19.1 PPI Tool Instructions.docx DOCX document
Data Pkg 3 TRICARE Retail Pharmacy Claim Volume.xlsx XLSX spreadsheet
TPharm5 Draft Section C 20191202.docx DOCX document
Data Pkg 6 - MOP Utilization.xlsx XLSX spreadsheet
Attachment L-13 VA_Pharmacy_Listing_2019.xlsx XLSX spreadsheet
Attachment L-1.2 Non-Disclosure Agreement.docx DOCX document
Data Pkg 21 Enrolled Beneficiary Population.xlsx XLSX spreadsheet
TPharm5 Draft Section H 20191121.docx DOCX document
Data Pkg 10 - Compound Utilizers.xlsx XLSX spreadsheet
Show all 50

This notice has more attachments on GovTribe.

Notice history

Notice Type Posted
TRICARE Pharmacy Services, 5th Generation (TPharm5) Award Award Notice
TRICARE Pharmacy Services, 5th Generation (TPharm5) Latest solicitation Solicitation
TRICARE Pharmacy Services, 5th Generation (TPharm5) Pre-Solicitation
DRAFT RFP TRICARE Pharmacy Services, 5th Generation (TPharm5) This notice · Original Special Notice

On GovTribe

Work this opportunity on GovTribe

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity
Try for free Login